Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients

Arthritis Care and Research

Volumn 65, Issue 2, 2013, Pages 299-303

  Chu, Li Hao ^a   Portugal, Cecilia ^a   Kawatkar, Aniket A ^a   Stohl, William ^b   Nichol, Michael B ^b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIAN AMERICAN; CAUCASIAN; COMPARATIVE EFFECTIVENESS; ETHNIC DIFFERENCE; FEMALE; HEALTH INSURANCE; HISPANIC; HOSPITAL PATIENT; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOME ASSESSMENT; PRESCRIPTION; RACE DIFFERENCE; REHABILITATION CARE; RHEUMATOID ARTHRITIS; SOCIAL STATUS; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CALIFORNIA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LOGISTIC MODELS; MALE; MEDICAID; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84873108593     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21798     Document Type: Article

References (18)

1. Bruce B, Fries JF, Murtagh KN,. Health status disparities in ethnic minority patients with rheumatoid arthritis: a cross-sectional study. J Rheumatol 2007; 34: 1475-9.
2. Constantinescu F, Goucher S, Weinstein A, Fraenkel L,. Racial disparities in treatment preferences for rheumatoid arthritis. Med Care 2009; 47: 350-5.
3. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
4. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-34.
5. Strand V, Singh JA,. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010; 70: 121-45.
6. Bailit Health Purchasing. Monitoring Medi-Cal: recommendations for measuring the performance of California's Medicaid program. URL: http://www.chcf.org/publications/2011/01/monitoring-medical-recommendations- measuring-performance.
7. California Healthcare Foundation. Medi-Cal facts and figures. URL: http://www.chcf.org/publications/2009/09/medical-facts-and-figures.
8. Singh JA, Holmgren AR, Noorbaloochi S,. Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004; 51: 952-7.
9. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9.
10. Arthritis Foundation. Arthritis Today drug guide. URL: http://www.arthritistoday.org/treatments/drug-guide/index.php.
11. Ting G, Schneeweiss S, Scranton R, Katz JN, Weinblatt ME, Young M, et al. Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study. Arthritis Res Ther 2008; 10: R95.
12. Constantinescu F, Goucher S, Weinstein A, Smith W, Fraenkel L,. Understanding why rheumatoid arthritis patient treatment preferences differ by race. Arthritis Rheum 2009; 61: 413-8.
13. Martin RW, Head AJ, Rene J, Swartz TJ, Fiechtner JJ, McIntosh BA, et al. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. J Rheumatol 2008; 35: 618-24.
14. Yazici Y, Kautiainen H, Sokka T,. Differences in clinical status measures in different ethnic/racial groups with early rheumatoid arthritis: implications for interpretation of clinical trial data. J Rheumatol 2007; 34: 311-5.
15. Ang DC, Paulus HE, Louie JS,. Patient's ethnicity does not influence utilization of effective therapies in rheumatoid arthritis. J Rheumatol 2006; 33: 870-8.
16. Bolen J, Schieb L, Hootman JM, Helmick CG, Theis K, Murphy LB, et al. Differences in the prevalence and severity of arthritis among racial/ethnic groups in the United States: National Health Interview Survey, 2002, 2003, and 2006. Prev Chronic Dis 2010; 7: A64.
17. Chilton F, Collett RA,. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1-14.
18. Tutuncu Z, Reed G, Kremer J, Kavanaugh A,. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006; 65: 1226-9.